Please login to the form below

Not currently logged in

Strong Tagrisso soothes AZ as US sales plummet

Sales decline 34% in the US due to low-cost copies of Crestor


Strong sales of new lung cancer drug Tagrisso proved a balm to AstraZeneca in the first quarter, as generic competition cut away a third of its US sales.

Buoyant uptake for Tagrisso (osimertinib) in the US and EU saw the drug reach $171m in sales, up from $51m a year ago, to become AZ's third-biggest cancer drug.

Tagrisso has just recently seen its conditional approvals in the US and EU for second-line non-small cell lung cancer (NSCLC) treatment converted to full approval, and is due to get a read-out in its first-line NSCLC trial later this year - which analysts suggest could help drive sales to around $2bn a year. It also picked up new second-line approvals in Brazil, Hong Kong and Taiwan during the first quarter.

AZ needs Tagrisso and other growth-phase drugs such as ovarian cancer therapy Lynparza (olaparib) - which rose 30% to $57m in the quarter - to help offset dramatic declines in mature products that have lost patent protection. That impact was felt particularly strongly in the US, where sales declined 34% to $1.49bn thanks largely to the launch of low-cost copies of cholesterol drug Crestor (rosuvastatin) in the latter half of 2016.

Overall, AZ reported a 12% decrease in group revenues to $5.4bn in the first quarter, which was in line with analyst expectations, and the company said it is confident that the big year-on-year declines will start to recede in the second half of this year and into 2018.

AZ has been selling off older and non-core assets left and right as it pushes the accelerator on its R&D pipeline, and says it is entering a particularly productive period that could see six new drugs launched for cancer alone between 2014 and 2020 - including Lynparza and Tagrisso.

AZ is playing catch-up in the immuno-oncology sector, but lead candidate durvalumab - a PD-L1 inhibitor - is under regulatory review as a second-line therapy for patients with locally-advanced or metastatic urothelial carcinoma (mUC), with an FDA verdict due in the second quarter of this year.

It is also expecting phase III results from a combination trial of durvalumab with CTLA-4 inhibitor tremelimumab in third-line NSCLC in the second half of the year, with data readout from a first line combination trial due in 2018. Results from a study of durvalumab plus tremelimumab in first-line head and neck cancer are also expected before the end of 2017.

Meanwhile in its targeted oncology portfolio AZ is also expecting to file BTK inhibitor acalabrutinib for B-cell malignancies later this year, with MEK inhibitor selumetinib for thyroid cancer and   moxetumomab pasudotox for hairy cell leukaemia due for first regulatory submissions in 2018.

Commenting on the first-quarter performance, AZ's chief executive Pascal Soriot said: "The pipeline continued to deliver in what we expect will be a pivotal year for AZ as we announced important developments, in particular in oncology."

"Importantly, we anticipate the significant progress of the pipeline to continue, including our immuno-oncology and targeted treatments," he added.

Article by
Phil Taylor

28th April 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

Solaris Health looks at the gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...